Precision diagnosis and treatment of cholestatic liver disease and frontier exploration
- VernacularTitle:胆汁淤积性肝病精准诊疗与前沿探索
- Author:
Liangjun ZHANG
1
;
Qiong PAN
1
;
Jin CHAI
1
Author Information
- Publication Type:Journal Article
- Keywords: Cholestasis; Precision Medicine; Diagnosis; Therapeutics
- From: Journal of Clinical Hepatology 2025;41(7):1241-1245
- CountryChina
- Language:Chinese
- Abstract: Cholestatic liver disease(CLD)encompasses a range of acute and chronic disorders characterized by impaired bile formation and/or flow.If left untreated,it may progress to cirrhosis and even liver failure.In recent years,with the development of molecular biology and omics technologies,the diagnosis and treatment of CLD are entering the era of precision medicine.This article reviews the advances in the diagnosis of CLD based on genetic testing and omics biomarkers and summarizes the latest studies and clinical trials on hydrophilic bile acid,FXR agonist,PPAR agonist,antibiotics,and novel molecules in targeted therapy for CLD.In the future,integrating omics data and implementing individualized diagnosis and treatment will be the main directions in precision medicine for CLD.This article aims to provide a reference for basic research and clinical translation in the field of CLD.
